Share Price and Basic Stock Data
Last Updated: February 14, 2026, 8:42 pm
| PEG Ratio | 14.81 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Glenmark Pharmaceuticals Ltd operates in the competitive pharmaceuticals sector, with a current market price of ₹1,958 and a market capitalization of ₹55,233 Cr. The company reported a total revenue of ₹12,990 Cr for the fiscal year ending March 2023, which increased to ₹13,322 Cr for the fiscal year 2025. The trailing twelve months (TTM) revenue stood at ₹15,955 Cr, reflecting a growth trajectory. Quarterly sales figures indicate fluctuations, with sales peaking at ₹3,434 Cr in September 2024, before declining to ₹2,507 Cr in December 2023. Notably, the operating profit margin (OPM) showed variability, hitting a low of -8% in December 2023 but recovering to 39% by September 2025, showcasing the company’s ability to rebound from challenging periods. This volatility in sales and profitability underscores the impact of market dynamics and operational efficiency on Glenmark’s revenue performance.
Profitability and Efficiency Metrics
Glenmark’s profitability metrics reveal a mixed performance. The net profit for the fiscal year ending March 2023 was ₹377 Cr, which improved to ₹1,047 Cr by March 2025. However, the company faced significant challenges in the interim, reporting a net loss of ₹1,434 Cr for the fiscal year 2024. The return on equity (ROE) stood at 15.8%, while the return on capital employed (ROCE) recorded at 19.4% demonstrates effective capital utilization. Operating profit margins fluctuated, with a high of 39% in September 2025, illustrating improved operational efficiency. The cash conversion cycle (CCC) averaged 129 days, indicating the time taken to convert inventory and receivables into cash, which is within a typical range for the industry. Despite these efficiency metrics, the inconsistent profitability highlights the need for robust operational strategies to stabilize earnings.
Balance Sheet Strength and Financial Ratios
Glenmark’s balance sheet reflects a conservative capital structure, with total borrowings of ₹1,224 Cr against reserves of ₹9,554 Cr. The debt-to-equity ratio stands at 0.24, indicating low leverage and financial prudence. The interest coverage ratio (ICR) of 11.90x suggests that the company can comfortably meet its interest obligations, a positive indicator of financial health. The price-to-book value (P/BV) ratio of 4.91x indicates that the market values Glenmark at a premium to its book value, reflecting investor confidence. Additionally, the current ratio of 1.56x suggests adequate liquidity to cover short-term liabilities. However, the fluctuation in reserves and borrowings indicates a need for careful management of financial resources to support growth while maintaining stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Glenmark Pharmaceuticals indicates a diverse ownership structure, with promoters holding 46.64% and foreign institutional investors (FIIs) holding 20.73%. Domestic institutional investors (DIIs) have increased their stake to 18.61%, reflecting growing confidence in the company’s prospects. Public shareholders account for 13.97%, with a total of 198,789 shareholders as of September 2025. The slight decline in promoter holdings from 46.65% to 46.64% over recent quarters suggests stability in their commitment to the company. The increase in DII participation indicates a positive shift in institutional sentiment, potentially driven by improved financial performance in recent quarters. This diverse ownership base is crucial for fostering investor confidence and enhancing market stability.
Outlook, Risks, and Final Insight
Glenmark Pharmaceuticals faces a dual-edged scenario in the near future. On one hand, the company’s strong recovery in profitability, highlighted by a net profit of ₹1,047 Cr for the fiscal year 2025, alongside robust efficiency metrics, positions it favorably within the pharmaceuticals sector. However, risks remain, particularly in the form of fluctuating sales and operational challenges that could impact future earnings stability. The company must navigate regulatory hurdles and competitive pressures in the market while maintaining operational efficiency. Strengths such as a solid balance sheet and improved investor confidence provide a buffer against these risks. Should Glenmark successfully leverage its operational efficiencies and manage its costs effectively, it can continue to enhance shareholder value and sustain growth. Conversely, any significant downturn in market conditions or operational setbacks could pose challenges to its recovery trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 137/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,402 Cr. | 312 | 479/192 | 71.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 338 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,956.81 Cr | 1,098.00 | 54.79 | 201.74 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 |
| Expenses | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 |
| Operating Profit | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 |
| OPM % | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% |
| Other Income | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 |
| Interest | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 |
| Depreciation | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 |
| Profit before tax | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 |
| Tax % | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% |
| Net Profit | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 |
| EPS in Rs | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 |
Last Updated: February 5, 2026, 9:46 pm
Below is a detailed analysis of the quarterly data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 3,901.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,047.00 Cr. (Sep 2025) to 3,901.00 Cr., marking a decrease of 2,146.00 Cr..
- For Expenses, as of Dec 2025, the value is 3,031.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,687.00 Cr. (Sep 2025) to 3,031.00 Cr., marking a decrease of 656.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 870.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,360.00 Cr. (Sep 2025) to 870.00 Cr., marking a decrease of 1,490.00 Cr..
- For OPM %, as of Dec 2025, the value is 22.00%. The value appears to be declining and may need further review. It has decreased from 39.00% (Sep 2025) to 22.00%, marking a decrease of 17.00%.
- For Other Income, as of Dec 2025, the value is -140.00 Cr.. The value appears strong and on an upward trend. It has increased from -1,184.00 Cr. (Sep 2025) to -140.00 Cr., marking an increase of 1,044.00 Cr..
- For Interest, as of Dec 2025, the value is 41.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.00 Cr. (Sep 2025) to 41.00 Cr., marking a decrease of 25.00 Cr..
- For Depreciation, as of Dec 2025, the value is 154.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 141.00 Cr. (Sep 2025) to 154.00 Cr., marking an increase of 13.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 534.00 Cr.. The value appears to be declining and may need further review. It has decreased from 967.00 Cr. (Sep 2025) to 534.00 Cr., marking a decrease of 433.00 Cr..
- For Tax %, as of Dec 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Sep 2025) to 24.00%, marking a decrease of 13.00%.
- For Net Profit, as of Dec 2025, the value is 403.00 Cr.. The value appears to be declining and may need further review. It has decreased from 610.00 Cr. (Sep 2025) to 403.00 Cr., marking a decrease of 207.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 14.29. The value appears to be declining and may need further review. It has decreased from 21.63 (Sep 2025) to 14.29, marking a decrease of 7.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 15,955 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 11,854 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 4,101 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 26% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -1,811 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 244 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 519 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,527 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,010 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 35.78 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 4:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 9,554 |
| Borrowings | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,627 | 1,231 | 2,473 | 1,224 |
| Other Liabilities | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,228 | 5,279 | 4,669 | 8,196 |
| Total Liabilities | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
| Fixed Assets | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,202 | 4,210 | 4,487 | 5,210 |
| CWIP | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,251 | 662 | 835 | 695 |
| Investments | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 11,830 | 8,697 | 10,613 | 13,054 |
| Total Assets | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
Below is a detailed analysis of the balance sheet data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,554.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,821.00 Cr. (Mar 2025) to 9,554.00 Cr., marking an increase of 733.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,224.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,473.00 Cr. (Mar 2025) to 1,224.00 Cr., marking a decrease of 1,249.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8,196.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,669.00 Cr. (Mar 2025) to 8,196.00 Cr., marking an increase of 3,527.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 19,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,487.00 Cr. (Mar 2025) to 5,210.00 Cr., marking an increase of 723.00 Cr..
- For CWIP, as of Sep 2025, the value is 695.00 Cr.. The value appears to be declining and may need further review. It has decreased from 835.00 Cr. (Mar 2025) to 695.00 Cr., marking a decrease of 140.00 Cr..
- For Investments, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2025) to 42.00 Cr., marking a decrease of 14.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,613.00 Cr. (Mar 2025) to 13,054.00 Cr., marking an increase of 2,441.00 Cr..
- For Total Assets, as of Sep 2025, the value is 19,002.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
Notably, the Reserves (9,554.00 Cr.) exceed the Borrowings (1,224.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 12,636,078 | 2.78 | 2571.69 | N/A | N/A | N/A |
| Invesco India Midcap Fund | 1,864,031 | 3.68 | 379.37 | N/A | N/A | N/A |
| Invesco India Contra Fund | 1,850,088 | 1.82 | 376.53 | 1,662,235 | 2025-12-14 11:28:18 | 11.3% |
| Invesco India Large & Mid Cap Fund | 1,342,939 | 2.92 | 273.31 | N/A | N/A | N/A |
| HDFC Manufacturing Fund | 1,280,000 | 2.37 | 260.51 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 1,048,046 | 0.74 | 213.3 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 989,000 | 3.28 | 201.28 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 952,877 | 1.02 | 193.93 | 463,185 | 2025-12-08 07:53:24 | 105.72% |
| Mirae Asset Healthcare Fund | 941,043 | 6.91 | 191.52 | 956,043 | 2025-12-15 03:13:43 | -1.57% |
| HDFC Balanced Advantage Fund | 885,046 | 0.17 | 180.12 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Pharmaceuticals Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.8 (Industry average Stock P/E: 54.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/2, Mahalaxmi Chambers, Mumbai Maharashtra 400026 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director |
| Mr. Anurag Mantri | Executive Director & Global CFO |
| Mrs. B E Saldanha | Non Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. Pradeep Kumar Sinha | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd's intrinsic value (as of 15 February 2026) is ₹907.63 which is 54.57% lower the current market price of ₹1,998.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹56,372 Cr. market cap, FY2025-2026 high/low of ₹2,286/1,275, reserves of ₹9,554 Cr, and liabilities of ₹19,002 Cr.
What is the Market Cap of Glenmark Pharmaceuticals Ltd?
The Market Cap of Glenmark Pharmaceuticals Ltd is 56,372 Cr..
What is the current Stock Price of Glenmark Pharmaceuticals Ltd as on 15 February 2026?
The current stock price of Glenmark Pharmaceuticals Ltd as on 15 February 2026 is ₹1,998.
What is the High / Low of Glenmark Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glenmark Pharmaceuticals Ltd stocks is ₹2,286/1,275.
What is the Stock P/E of Glenmark Pharmaceuticals Ltd?
The Stock P/E of Glenmark Pharmaceuticals Ltd is 20.8.
What is the Book Value of Glenmark Pharmaceuticals Ltd?
The Book Value of Glenmark Pharmaceuticals Ltd is 340.
What is the Dividend Yield of Glenmark Pharmaceuticals Ltd?
The Dividend Yield of Glenmark Pharmaceuticals Ltd is 0.13 %.
What is the ROCE of Glenmark Pharmaceuticals Ltd?
The ROCE of Glenmark Pharmaceuticals Ltd is 19.4 %.
What is the ROE of Glenmark Pharmaceuticals Ltd?
The ROE of Glenmark Pharmaceuticals Ltd is 15.8 %.
What is the Face Value of Glenmark Pharmaceuticals Ltd?
The Face Value of Glenmark Pharmaceuticals Ltd is 1.00.